MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release second quarter 2021
MONROVIA, Calif. --(BUSINESS WIRE)--May 27, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief
-- Vir Biotechnology and GlaxoSmithKline's investigational SARS-CoV-2 antibody, engineered with the Xencor XmAb ® Fc technology, Xtend™, is authorized for treatment of mild-to-moderate COVID-19 in high-risk adults and pediatric patients -- -- Treatment with sotrovimab resulted in an 85% reduction
MONROVIA, Calif. --(BUSINESS WIRE)--May 25, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it has entered into a technology license agreement
MONROVIA, Calif. --(BUSINESS WIRE)--May 12, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat , Ph.D., president and chief
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--May 5, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in a
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 28, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will release first quarter 2021
MONROVIA, Calif. --(BUSINESS WIRE)--Apr. 10, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple
MONROVIA, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on three XmAb ®
